North China Pharmaceutical Genetech Biotechnology

North China Pharmaceutical Group GeneTech Biotechnology Co., Ltd. is a prominent Chinese biotechnology firm and a core subsidiary of the North China Pharmaceutical Group (NCPC). Founded in 1994 and headquartered in Shijiazhuang, the company focuses on the development and commercialization of recombinant protein therapeutics and vaccines. Its product portfolio includes widely used treatments such as recombinant human erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), and a recombinant hepatitis B vaccine produced using CHO cells. Notably, the company recently launched Xunke (ormutivimab), the first human rabies monoclonal antibody approved in China for post-exposure prophylaxis. GeneTech operates advanced GMP-certified manufacturing facilities and maintains a strong presence in the domestic hematology and infectious disease markets.